Product description
Cagrilintide (also known as AM833 / NN9838) is a long-acting synthetic amylin analog peptide developed for metabolic and obesity research applications. It is a once-weekly injectable research peptide designed to mimic the natural hormone amylin, which plays a key role in appetite regulation, gastric emptying, and post-meal satiety signaling.
Cagrilintide is widely studied as a standalone compound and as part of combination therapy (notably with GLP-1 receptor agonists such as semaglutide) for enhanced metabolic outcomes.
Mechanism of Action
Cagrilintide acts as a dual amylin and calcitonin receptor agonist, targeting appetite-regulating centers in the brainstem (area postrema and hypothalamus).
Its main mechanisms include:
- Activates amylin receptors (AMY1R, AMY2R, AMY3R)
- Enhances satiety signaling and early fullness
- Slows gastric emptying
- Reduces post-meal glucagon secretion
- Decreases food intake and calorie consumption
Unlike GLP-1 peptides, Cagrilintide works through a completely separate metabolic pathway, making it highly synergistic in combination research.
Disclaimer
This product is intended for laboratory research and scientific purposes only. It is not intended for human consumption, medical use, diagnosis, treatment, or prevention of any disease. Buyers are responsible for ensuring compliance with all applicable laws and regulations in their respective jurisdictions.
Reviews
There are no reviews yet.